RBC Capital on Ideaya Biosciences (IDYA): 'We remain positive on the upcoming data readout'

March 23, 2026 2:21 PM

RBC Capital analyst Leonid Timashev reiterated an Outperform rating and $49.00 price target on Ideaya Biosciences (NASDAQ: IDYA).The analyst comments ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found